Margalith M, Simkin M, Shohat G, Teitz Y; International Conference on AIDS.
Int Conf AIDS. 1998; 12: 1119-20 (abstract no. 60651).
Department of Virology Faculty Health Sciences, Ben-Gurion University of the Negev Beer-Sheva, Tel-Aviv, Israel.
OBJECTIVE: To provide new non cytotoxic and efficient anti-CMV drugs. DESIGN: Newly synthesized two Thiosemicarbazone derivatives (TSCDs) were chosen for study. METHODS: Human foreskin fibroblasts (HFF) and engineered human osteosarcoma cells (HOS-HXG) which contain a defective HIV-1 provirus genome were used. CMV (Towne strain) antigens were measured in the infected cells by immunoperoxidase (IPA) and immunofuorescence (IFA) assays and infectious CMV in the culture supernatant fluid was measured by titration on HFF cells. HIV-1 p24 antigen was detected by enzyme linked immunosorbent assay (ELISA). RESULTS: The two TSCDs compounds, showed inhibitory effect on CMV antigens production, at non cytotoxic concentrations. The first derivative at 8 micrograms/ml inhibited CMV antigens and infectious CMV synthesis in 93% and in 92% of infected HFF cells respectively. In HOS-HXG cells, at 2 micrograms/ml, it inhibited CMV antigens and infectious CMV synthesis in 67% and in 80% of infected cells respectively. The second derivative showed less efficient inhibitory effect on CMV antigens production. The two compounds, at the same concentration which inhibited CMV replication, had no inhibitory effect on HIV-1 p24 antigen level in HOS-HXG cells. This may suggest that the HIV-1 p24 gene, in HOS-HXG cells, behaves like a cellular and not as viral gene. The parental drug M-IBT, which inhibited pox viruses, had no effect on CMV replication and HIV-1 p24 synthesis. CONCLUSIONS: These TSCDs inhibited CMV replication, at a concentration range which had no effect on cell growth. Further studies are needed in order to establish the TSCDs as anti-CMV drugs for treatment.
Publication Types:
Keywords:
- Antigens, Viral
- Cytomegalovirus
- Cytomegalovirus Infections
- Enzyme-Linked Immunosorbent Assay
- HIV-1
- Humans
- Immunoenzyme Techniques
- Proviruses
- Thiosemicarbazones
- immunology
Other ID:
UI: 102232599
From Meeting Abstracts